BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. In certain human cancer types, Src is associated with cancer progression and refractory cancer. To improve the prognoses of NSCLC patients, we evaluated Src kinase-associated phosphoprotein 2 (SKAP2), a factor associated with integrin-stimulated cytoskeletal rearrangement, as a new therapeutic target. MATERIALS AND METHODS: We performed immunohistochemistry for SKAP2 in 99 NSCLC samples and evaluated the relationship between SKAP2 expression, clinicopathological factors and prognosis. RESULTS: Higher SKAP2 expression was detected in cancerous tissues and was predominantly expressed in the cytoplasm. Elevated SKAP2 expression levels were associated with poor prognosis (p=0.007) and shorter survival time after recurrence (p=0.035). High SKAP2 expression was an independent prognostic factor in NSCLC patients (p=0.027). CONCLUSION: High SKAP2 expression levels in NSCLC tissues could be a powerful biomarker of poor prognosis. Therefore, SKAP2 is a promising candidate molecular target for NSCLC treatment. Copyright
BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. In certain humancancer types, Src is associated with cancer progression and refractory cancer. To improve the prognoses of NSCLCpatients, we evaluated Src kinase-associated phosphoprotein 2 (SKAP2), a factor associated with integrin-stimulated cytoskeletal rearrangement, as a new therapeutic target. MATERIALS AND METHODS: We performed immunohistochemistry for SKAP2 in 99 NSCLC samples and evaluated the relationship between SKAP2 expression, clinicopathological factors and prognosis. RESULTS: Higher SKAP2 expression was detected in cancerous tissues and was predominantly expressed in the cytoplasm. Elevated SKAP2 expression levels were associated with poor prognosis (p=0.007) and shorter survival time after recurrence (p=0.035). High SKAP2 expression was an independent prognostic factor in NSCLCpatients (p=0.027). CONCLUSION: High SKAP2 expression levels in NSCLC tissues could be a powerful biomarker of poor prognosis. Therefore, SKAP2 is a promising candidate molecular target for NSCLC treatment. Copyright
Authors: Kathryn L Penney; Barbara L Banbury; Stephanie Bien; Tabitha A Harrison; Xinwei Hua; Amanda I Phipps; Wei Sun; Mingyang Song; Amit D Joshi; Steven R Alberts; Carmen J Allegra; James Atkins; Linda H Colangelo; Thomas J George; Richard M Goldberg; Peter C Lucas; Suresh G Nair; Qian Shi; Frank A Sinicrope; Norman Wolmark; Greg Yothers; Ulrike Peters; Polly A Newcomb; Andrew T Chan Journal: Clin Gastroenterol Hepatol Date: 2019-12-04 Impact factor: 11.382
Authors: Lamia Mouhid; Marta Gómez de Cedrón; Elena García-Carrascosa; Guillermo Reglero; Tiziana Fornari; Ana Ramírez de Molina Journal: PLoS One Date: 2019-03-26 Impact factor: 3.240